News
MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly injection treatment.
7d
Investor's Business Daily on MSNWhy S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter
Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...
Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...
Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...
Apart from the meaningful weight loss, MariTide showcased a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2% in people who have obesity and T2D.
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves once each week. In newly released clinical trial data, Amgen’s once-monthly ...
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results